Author Index

Abdillahi, H. *see* Saukkonen, K., 325
Adeiga, A. *see* Harry, T.O., 329
Aggarwal, P. *see* Madhusudana, S.N., 478
Ahsan, C.R. *see* Ciznar, I., 111
Ahuja, S. *see* Bhandari, S.K., 478
Aizawa, C. *see* Tamura, S.I., 503
Aizawa, C. *see* Tamura, S., 257, 314
Ajjan, N. and Pilet, Ch. Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and the new vaccine grown on Vero cells, 125
Akerblom, L. *see* Osterhaus, A., 137
Akerblom, L. *see* Pyle, S.W., 465
Akerblom, L., Stromstedt, K., Hoglund, S., Osterhaus, A. and Morein, B. Formation and characterization of FeLV ISCOMs, 142
Akinlade, H. O. *see* Harry, T.O., 329
Alam, A., Singh, O. and Talwar, G.P. Stability of an anti-fertility vaccine consisting of gonadotropin subunits linked to tetanus toxoid, 129
Alpatova, G.A. *see* Elbert, L.B., 477
Alving, C.R. *see* Richards, R.L., 506
Amosenko, F.A. *see* Elbert, L.B., 477
Ansaruzzaman, M. *see* Clements, J.C., 117
Arondel, J. *see* Sansonetti, P.J., 443
Arthur, L.O. *see* Pyle, S.W., 465
Artursson, P. *see* O'Hagan, D.T., 421
Arya, S.C. Glutaraldehyde in whole-cell *Bordetella pertussis* vaccine, 486
Arya, S.C. Putative failures of recombinant DNA hepatitis B vaccines, 164
Arya, S.C. Failures of postexposure rabies and other immunotherapies in developing countries, 372
Ashworth, L.A.E. *see* Robinson, A., 491
Attridge, S.R. *see* Sharma, D.P., 451
Auza, N. *see* Bellinzoni, R.C., 263
Azuma, I.*see* Onuma, M., 121
Azuma, I. *see* Iida, J., 225, 229
Azuma, I. *see* Sakurai, T., 269
Azuma, I. *see* Maeda, H., 275
Azuma, I. *see* Ishihara, C., 309

Baggs, R.B. *see* Murphy, B.R., 533
Baljet, M. *see* Beyer, W.E.P., 385
Bandman, O.E. *see* Stanislavsky, E.S., 562
Baro, N. *see* Bellinzoni, R.C., 263
Barret, A.D.T., Pryde, A., Medlen, A.R., Ledger, T.N., Whitby, J.E., Gibson, C.A., DeSilva, M., Groves, D.J., Langley, D.J. and Minor, P.D. Examination of the envelope glycoprotein of yellow fever vaccine viruses with monoclonal antibodies, 333
Bellinzoni, R.C., Blackhall, J., Baro, N., Auza, N., Mattion, M., Casaro, A., La Torre, J.L. and Scodeller, E. Efficacy of an inactivated oil-adjuvanted rotavirus vaccine in the control of calf diarrhoea in beef herds in Argentina, 263
Berger, R. *see* Sturchler, D., 457
Berman, S.L. *see* Richards, R.L., 506
Bess, Jr, J.W. *see* Pyle, S.W., 465
Beuvery, E.C. *see* Speijers, G.J.A., 364
Beyer, W.E.P., Palache, A.M., Baljet, M. and Masurel, N. Antibody induction by influenza vaccines in the elderly: a review of the literature, 385
Bhandari, S.K., Sharma, S.B., Ahuja, S. and Saxena, S.N. Tetanus toxoid (adsorbed) – a stability study, 478
Blackhall, J. *see* Bellinzoni, R.C., 263
Bohbot, J.M. *see* Levy, D.A., 337
Boolk, V.F. *see* Stanislavsky, E.S., 562
Boriskin, Y.S. *see* Sidorenko, E.S., 554
Bortner, D. *see* Whetstone, C., 527
Botta, V. *see* Torre, D., 102
Boxall, E.H. Vaccine hypersensitivity or coincidental virus infection, 77
Broggini, M. *see* Torre, D., 102
Brown, J. *see* Dreesen, D.W., 397
Brugge, H.N. *see* Visser, I.K.G., 521
Buckler-White, A.J. *see* Murphy, B.R., 557
Burny, A. *see* Merza, M.S., 22
Butler, A.V.J. *see* Herbert, M., 395

Cameron, D. *see* Ganguly, R., 462
Camussi, G. *see* Piedra, P.A., 34
Cao, M. *see* Kusumi, T., 351
Casaro, A. *see* Bellinzoni, R.C., 263
Catalan, F. *see* Levy, D.A., 337
Caul, E.O. *see* Herbert, M., 395
Cellesi, C., Zanchi, A., Michelangeli, C., Giovannoni, F., Sansoni, A. and Rossolini, G.M. Immunity to diphtheria in a sample of adult population from central Italy, 417
Chakraborty, J. *see* Clements, J.C., 117
Chanock, R.M. *see* Murphy, B.R., 533
Charbit, A. *see* Leclerc, C., 242
Chatfield, S.N., Strugnell, R.A. and Dougan, G. Live *Salmonella* as vaccines and carriers of foreign antigenic determinants, 495
Chauvaux, S. *see* Lambre, C.R., 104
Chomchey, P. *see* Wilde, H., 10
Choomkasien, P. *see* Wilde, H., 49
Chulay, J.D. *see* Richards, R.L., 506
Chutivongse, S. *see* Wilde, H., 10, 49
Chutivongse, S. *see* Phanuphak, P., 253
Chutivongse, S. and Wilde, H. Post-exposure rabies vaccination during pregnancy: experience with 21 patients, 546
Ciznar, I. *see* Clemens, J.C., 117
Ciznar, I., Hussain, N., Ahsan, C.R., Kay, B.A., Clemens, J.D. and Sack, D.A. Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. 1. Cross-reacting antigens of members of family Vibrionaceae and the vaccines, 111
Clemens, J. *see* Holmgren, J., 94
Clemens, J.D. *see* Ciznar, I., 111
Clemens, J.C, Harris, J.R., Kay, B.A., Chakraborty, J., Sack, D.A., Ansaruzzaman, M., Rahman, R., Ciznar, I., Svennerholm, A.-M. and Holmgren, J. Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. 11. Field evaluation of cross-protection against other members of the Vibrionaceae family, 117
Coleman, P.J. *see* Shaw Jr, F.E., 425
Contreras, G. Effect of the administration of oral poliovirus vaccine on infantile diarrhoea mortality, 211
Crainic, R. *see* Phalipon, A., 132

d'Hinterland, L.D. *see* Levy, D.A., 337
Dal Monte, P.R. and Szoka Jr, F.C. Antigen presentation by B cells and macrophages of cytochrome *c* and its antigenic fragment when conjugated to the surface of liposomes, 401
Danse, L.H.J.C. *see* Speijers, G.J.A., 364
Davis, S.S. *see* O'Hagan, D.T., 213, 421
de Monzon, M.A. *see* Hadler, S.C., 106
de Vries, P. *see* Visser, I.K.G., 521
Deo, M.G. ICRC 'anti-leprosy vaccine', 92
DeSilva, M. *see* Barret, A.D.T., 333
Dorofeeva, L.V. *see* Sidorenko, E.S., 554
Dougan, G. *see* Chatfield, S.N., 495
Douglas Jr, R.G. *see* Gross, P.A., 303
Dreesen, D.W. *see* Fishbein, D.B., 437
Dreesen, D.W., Fishbein, D.B., Kemp, D.T. and Brown, J. Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization, 397
Duque, H., Marshall, R.L., Israel, B.A. and Letchworth, G.J. Effects of formalin inactivation on bovine herpesvirus-1 glycoproteins and antibody response elicited by formalin-inactivated vaccines in rabbits, 513

Edvabnaya, L.S. *see* Stanislavsky, E.S., 562
El Guink, N., Kris, R.M., Goodman-Snitkoff, G., Small Jr, P.A. and Manniono, R.J. Intranasal immunization with proteoliposomes protects against influenza, 147
Elbert, L.B., Terletskaya, E.N., Timofeev, A.V., Mironova, L.L., Khapchaev, U.Kh., Amosenko, F.A., Svitkin, Y.V., Alpatova, G.A., Krutyanskaya, G.L. Inactivated vaccine against tick-borne encephalitis (TBE) derived from heterploid continuous monkey cell line, 477
Erturk, M., Welch, M.J., Phillpotts, R.J. and Jennings, R. Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents, 431

0264-410X/89/060577-08 $03.00
© 1989 Butterworth & Co. (Publishers) Ltd

Esdaile, J. *see* Lifely, M.R., 17
Etlinger, H. *see* Sturchler, D., 457

Faden, H.S. *see* Piedra, P.A., 34
Fernandez, M. *see* Robinson, A., 321
Fernex, M. *see* Sturchler, D., 457
Finne, J. *see* Hayrinen, J., 217
Fischinger, P.J. *see* Pyle, S.W., 465
Fishbein, D.B. *see* Dreesen, D.W., 397
Fishbein, D.B., Dreesen, D. W., Homes, D.E., Pacer, R.E., Ley, A.B., Yager, P.A., Sumner, J.W., Reid-Sanden, F.L., Sanderlin, D.W. and Tong, T.C. Human diploid cell rabies vaccine purified by zonal centrifugation: A controlled study of antibody response and side effects following primary and booster preexposure immunizations, 437
Fritzell, B. *see* Harry, T.O., 329
Fujisawa, Y. *see* Hazama, M., 567
Funato, H. *see* Tamura, S.I., 503
Funato, H. *see* Tamura, S., 314
Funnell, S.G.P. *see* Robinson, A., 321
Furman, B.L. *see* Sidey, F.M., 237

Galazka, A. Loss of potency of vaccines at elevated temperatures, 479
Ganguly, R. and Cameron, D. Factors affecting immunization rate in a cohort of elderly veterans: a retrospective pilot study of influenza vaccine compliance, 462
Gibson, C.A. *see* Barret, A.D.T., 333
Giovannoni, F. *see* Cellesi, C., 417
Glikmann, G. *see* Pedersen, I.R., 345
Good, M.F. and Miller, L.H. Involvement of T cells in malaria immunity: implications for vaccine development, 3
Goodman-Snitkoff, G. *see* El Guink, N., 147
Gorringe, A.R. *see* Robinson, A., 321
Goto, Y. *see* Tsujimoto, M., 39
Gotoh, H. *see* Watanabe, K., 53
Granstrom, M. *see* Hederstedt, B., 349
Griffith, A.H. Permanent brain damage and pertussis vaccination: is the end of the saga in sight? 199
Griffith, A. H. Pertussis vaccines and permanent brain damage, 486
Groen, J. *see* Visser, I.K.G., 521
Gross, P.A., Quinnan Jr, G.V., Weksler, M.E., Setia, U. and Douglas Jr, R.G. Relation of chronic disease and immune response to influenza vaccine in the elderly, 303
Groves, D.J. *see* Barret, A.D.T., 333
Guess, H.A. *see* Lydick, E., 549
Guess, H.A. *see* Shaw Jr, F.E., 425

Hadler, S.C. *see* Shaw Jr, F.E., 425
Hadler, S.C., de Monzon, M.A., Lugo, D.R. and Perez, M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians, 106
Hall, R.H. *see* Sharma, D.P., 451
Harris, J.R. *see* Clemens, J.C., 117
Harry, T.O., Nasidi, A., Fritzell, B., Akinlade, H.O., Nereli, B., Rollins, P., Sureau, P. and Adeiga, A. Trial of economical regimens of suckling mouse brain rabies vaccine post-exposure prophylaxis in Lagos, Nigeria, 329
Hasegawa, A. *see* Maeda, H., 275
Hayre, M.D. *see* Richards, R.L., 506
Hayrinen, J., Pelkonen, S. and Finne, J. Structural similarity of the type-specific group B streptococcal polysaccharides and the carbohydrate units of tissue glycoproteins: evaluation of possible cross-reactivity, 217
Hazama, M., Takaoki, M., Ohfune, K., Hinuma, S. and Fujisawa, Y. Immunogenicity of a new type of yeast-derived hepatitis B vaccine consisting of M (pre-S2+S) protein particles, 567
Hederstedt, B. and Granstrom, M. Adverse reactions and antibody response to an acellular pertussis toxoid vaccine in adult volunteers, 349
Helleman, P.W. *see* Speijers, G.J.A., 364
Hemachudha, T. *see* Wilde, H., 49
Herbert, M., Butler, A.V.J., Roome, A.P.C.H. and Caul, E.O. Comparison of intradermal and intramuscular hepatitis B vaccination in university students, 395
Hess, G. *see* Wiesmuller, K.-H., 29
Hildreth, S.W. *see* Murphy, B.R., 533
Hinuma, S. *see* Hazama, M., 567
Hockmeyer, W.T. *see* Richards, R.L., 506
Hofnung, M. *see* Leclerc, C., 242
Hoglund, S. *see* Merza, M.S., 22
Hoglund, S. *see* Akerblom, L., 142
Holmgren, J. *see* Clemens, J.C., 117
Holmgren, J. *see* Svennerholm, A.-M., 196
Holmgren, J., Clemens, J., Sack, D.A. and Svennerholm, A.-M. New cholera vaccines, 94
Homes, D.E. *see* Fishbein, D.B., 437
Hussain, N. *see* Ciznar, I., 111

Iida, J. *see* Ishihara, C., 309
Iida, J., Saiki, I., Ishihara, C. and Azuma, I. Prophylactic activity against Sendai virus infection and macrophage activation with lipophilic derivatives of *N*-acetylglucosaminylmuramyl tri- or tetrapeptides, 225
Iida, J., Saiki, I., Ishihara, C. and Azuma, I. Protective activity of recombinant cytokines against Sendai virus and herpes simplex virus (HSV) infections in mice, 229
Imanishi, J. *see* Kusumi, T., 351
Iorio, A.M., Rivosecchi, P., Zei, T., Neri, M. and Merletti, L. Immune response to trivalent inactivated influenza vaccine in young and elderly subjects, 341
Irons, L.I. *see* Robinson, A., 491
Ishida, H. *see* Sakurai, T., 269
Ishida, H. *see* Maeda, H., 275
Ishihara, C. *see* Iida, J., 225, 229
Ishihara, C., Iida, J., Mizukoshi, N., Yamamoto, N., Yamamoto, K., Kato, K. and Azuma, I. Effect of N^{α}-acetylmuramyl-L-alanyl-D-isoglutaminyl-N^{ϵ}-stearoyl-L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide treated mice, 309
Israel, B.A. *see* Duque, H., 513

Jarrett, O. *see* Osterhaus, A., 137
Jennings, R. *see* Erturk, M., 431
Jenson, A.B. *see* Murphy, B.R., 533
Johns, A. *see* Jones, A.E., 300
Jones, A.E., Johns, A., Magrath, D.I., Melville-Smith, M. and Sheffield, F. Durability of immunity to diphtheria, tetanus and poliomyelitis after a three dose immunization schedule completed in the first eight months of life, 300
Jung, G. *see* Wiesmuller, K.-H., 29
Just, M. *see* Sturchler, D., 457

Kaczorek, M. *see* Phalipon, A., 132
Kajiyama, K. *see* Watanabe, K., 53
Kaptsova, T.I. *see* Sidorenko, E.S., 554
Kato, K. *see* Ishihara, C., 309
Kawakami, Y. *see* Onuma, M., 121
Kay, B.A. *see* Ciznar, I., 111
Kay, B.A. *see* Clemens, J.C., 117
Kemp, D.T. *see* Dreesen, D.W., 397
Khaoplod, P. *see* Phanuphak, P., 249
Khapchaev, U.Kh. *see* Elbert, L.B., 477
Kikuta, K. *see* Tamura, S., 257
Kino, Y., Nozaki, C., Nakatake, H., Mizuno, K. and Mori, R. Immunogenicity of herpes simplex virus glycoprotein gB-1-related protein produced in yeast, 155
Kiso, M. *see* Maeda, H., 275
Klein, R.J. Reinjections and site-specific immunity in herpes simplex virus infection, 380
Knell, P. *see* Osterhaus, A., 137
Kobayashi, H. *see* Watanabe, K., 53
Kojima, A. *see* Watanabe, K., 53, 499
Kotani, S. *see* Tsujimoto, M., 39
Krajnc-Franken, M.A.M. *see* Speijers, G.J.A., 364
Kris, R.M. *see* El Guink, N., 147
Krutyanskaya, G.L. *see* Elbert, L.B., 477
Kubo, T. *see* Tsujimoto, M., 39
Kurata, H. *see* Tamura, S., 257
Kurata, K. *see* Tamura, S., 314
Kurata, T. *see* Tamura, S.I., 503
Kurata, T. *see* Tamura, S., 257
Kurata, T. *see* Tamura, S., 314
Kusumi, T., Yamada, A., Cao, M., Tanaka, A., Takenaka, H. and Imanishi, J. Enhancing effects of immunoactive peptide FR48217 on immunological responses to vaccination by inactivated influenza virus, 351
Kusumoto, S. *see* Tsujimoto, M., 39
Kuter, B.J. *see* Lydick, E., 549

La Torre, J.L. *see* Bellinzoni, R.C., 263
Lambre, C.R., Chauvaux, S. and Pilatte, Y. Fluorometric assay for the measurement of viral neuraminidase influenza vaccines, 104
Langley, D.J. *see* Barret, A.D.T., 333
Lawrence, L. *see* Murphy, B.R., 533
Leclerc, C., Charbit, A., Molla, A. and Hofnung, M. Antibody response to a foreign epitope expressed at the surface of recombinant bacteria: importance of the route of immunization, 242
Ledger, T.N. *see* Barret, A.D.T., 333
Leinonen, M. *see* Saukkonen, K., 325
Lerche, N.W. *see* Pyle, S.W., 465
Letchworth, G.J. *see* Duque, H., 513
Levine, M.M. *see* Sharma, D.P., 451
Levy, D.A., Bohbot, J.M., Catalan, F., Normier, G., Pinel, A.M. and d'Hinterland, L.D. Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis, 337
Ley, A.B. *see* Fishbein, D.B., 437
Lifely, M.R., Esdaile, J. and Moreno, C. Passive transfer of meningococcal group B polysaccharide antibodies to the offspring of pregnant rabbits and their protective role against infection with *Escherichia coli* K1, 17
Linne, T. *see* Merza, M.S., 22
London, W.T. *see* Murphy, B.R., 557
Lugo, D.R. *see* Hadler, S.C., 106
Lussier, G. *see* Trudel, M., 12
Lydick, E., Kuter, B.J., Zajac, B.A. and Guess, H.A. Association of steroid therapy with vaccine-associated rashes in children with acute lymphocytic leukaemia who received Oka/Merck varicella vaccine, 549

Madhusudana, S.N. *see* Tripathi, K.K., 372
Madhusudana, S.N., Aggarwal, P. and Tripathi, K.K. Failure of rabies postexposure treatment with purified chick embryo cell (PCEC) vaccine, 478
Maeda, H., Saiki, I., Ishida, H., Kiso, M., Hasegawa, A. and Azuma, I. Adjuvant activities of synthetic lipid A subunit analogue and its conjugates with muramyl dipeptide derivatives, 275
Magrath, D.I. *see* Jones, A.E., 300
Makela, M.J., Marusyk, R.G., Norrby, E., Tyrell, D.L.J. and Salmi, A.A. Antibodies to measles virus surface polypeptides in an immunized student population before and after booster vaccination, 541
Mandel, E.J. *see* Shaw, Jr, F.E., 425
Manniono, R.J. *see* El Guink, N., 147
Marshall, R.L. *see* Duque, H., 513
Marusyk, R.G. *see* Makela, M.J., 541
Masurel, N. *see* Beyer, W.E.P., 385
Matile, H. *see* Sturchler, D., 457
Mattion, M. *see* Bellinzoni, R.C., 263
McBride, B.W., Ridgeway, P., Phillpots, R. and Newell, D.G. Systemic and mucosal cell mediated immune responses against herpes simplex virus in vaccinated guinea-pigs detected by lympocyte proliferation and monoclonal antibodies against macrophages and T cells, 409
Medlen, A.R. *see* Barret, A.D.T., 333
Mele, A. *see* Stroffolini, T., 152
Melville-Smith, M. *see* Jones, A.E., 300
Merletti, L. *see* Iorio, A.M., 341
Merza, M.A., Linne, T., Hoglund, S., Portetelle, D., Burny, A. and Morein, B. Bovine leukaemia virus ISCOMs: biochemical characterization, 22
Michelangeli, C. *see* Cellesi, C., 417
Miller, J. *see* Whetstone, C., 527
Miller, L.H. *see* Good, M.F., 3
Miller, D.L., Wadsworth, M.J.H. and Ross, E.M. Pertussis vaccine and severe acute neurological illnesses, 487
Minor, P.D. *see* Barret, A.D.T., 333
Mironova, L.L. *see* Elbert, L.B., 477
Mitchell, G.H. Editorial: A vaccine for ovine cysticercosis, 379
Mizukoshi, N. *see* Ishihara, C., 309
Mizuno, K. *see* Kino, Y., 155
Mohr, F.E. *see* Shaw Jr, F.E., 425
Molla, A. *see* Leclerc, C., 242
Mordhorst, C.H. *see* Pedersen, I.R., 345
Morein, B. *see* Osterhaus, A., 137
Morein, B. *see* Merza, M.S., 22
Morein, B. *see* Akerblom, L., 142
Morein, B. *see* Pyle, S.W., 465
Moreno, C. *see* Lifely, M.R., 17
Mori, R. *see* Kino, Y., 155
Morita, M. *see* Watanabe, K., 53, 499
Murphy, B.R., Buckler-White, A.J., London, W.T. and Snyder, M.H. Characterization of the M protein and nucleoprotein genes of an avaian influenza A virus which are involved in host range restriction on monkeys, 557
Murphy, B.R., Sotnikov, A., Paradiso, P.R., Hildreth, S.W., Jenson, A.B., Baggs, R.B., Lawrence, L., Zubak, J.J., Chanock, R.M. and Prince, G.A. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease, 533
Murray, P.K. Molecular vaccines against animal parasites, 291

Nadon, F. *see* Trudel, M., 12
Nagamine, T. *see* Tamura, S.I., 503
Nagamine, T. *see* Tamura, S., 257, 314
Nakatake, H. *see* Kino, Y., 155
Nara, P.L. *see* Pyle, S.W., 465
Nasidi, A. *see* Harry, T.O., 329
Nereli, B. *see* Harry, T.O., 329
Neri, M. *see* Iorio, A.M., 341
Neurath, A.R., Seto, B. and Strick, N. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective, 234
Newell, D.G. *see* McBride, B.W., 409
Nigida Jr, S.M. *see* Pyle, S.W., 465
Normier, G. *see* Levy, D.A., 337
Norrby, E. *see* Makela, M.J., 541
Nozaki, C. *see* Kino, Y., 155

O'Hagan, D.T., Palin, K.J. and Davis, S.S. Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization, 213
O'Hagan, D.T., Palin, K., Davis, S.S., Artursson, P. and Sjoholm, I. Microparticles as potentially orally active immunological adjuvants, 421
Ogra, P.L. *see* Piedra, P.A., 34
Ohfune, K. *see* Hazama, M., 567
Okunaga, T. *see* Tsujimoto, M., 39
Onuma, M., Yamamoto, M., Yasutomi, Y., Takahashi, K., Kawakami, Y. and Azuma, I. Regression of bovine lymphosarcoma by treatment with cell-wall skeleton of *Nocardia rubra*, 121
Osterhaus, A. *see* Akerblom, L., 142
Osterhaus, A.D.M.E. *see* Visser, I.K.G., 521
Osterhaus, A., Weijer, K., Uytde-Haag, F., Knell, P., Jarrett, O., Akerblom, L. and Morein, B. Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine, 137
Osterhaus, A.D.M.E. A morbillivirus causing mass mortality in seals, 483

Pacer, R.E. *see* Fishbein, D.B., 437
Palache, A.M. *see* Beyer, W.E.P., 385
Palin, K. *see* O'Hagan, D.T., 213, 421
Panmuong, W. *see* Phanuphak, P., 253
Paradiso, P.R. *see* Murphy, B.R., 533
Pasquini, P. *see* Stroffolini, T., 152
Pedersen, I.R., Mordhorst, C.H., Glikmann, G. and von Magnus, H. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland, 345
Peklisova, L.V. *see* Obrosova-Servoa, N.P., 0
Pelkonen, S. *see* Hayrinen, J., 217
Perez, M. *see* Hadler, S.C., 106
Phalipon, A., Crainic, R. and Kaczorek, M. Expression of a poliovirus type 1 neutralization epitope on a diphtheria toxin fusion protein, 132
Phanpanich, T. *see* Phanuphak, P., 249, 253
Phanuphak, P., Khaoplod, P., Sriwanthana, B., Phanpanich, T., Wongurai, S. and Roumiantzeff, M. Immunoenhancement with combined rabies and aluminium-adjuvanted tetanus vaccines, 249
Phanuphak, P., Phanpanich, T., Wongurai, S., Sirivichayakul, S., Sriwanthana, B., Panmuong, W., Utaisen, O. and Chutivongse, S. Comparative immunogenicity study of four plasma-derived hepatitis B vaccines in Thai young adults, 253
Phillpots, R. *see* McBride, B.W., 409
Phillpotts, R.J. *see* Erturk, M., 431
Piedra, P.A., Faden, H.S., Camussi, G. Wong, D.T. and Ogra, P.L. Mech-

anism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus, 34
Pilatte, Y. *see* Lambre, C.R., 104
Pilet, Ch. *see* Ajjan, N., 125
Pinel, A.M. *see* Levy, D.A., 337
Pink, R. *see* Sturchler, D., 457
Poolman, J.T. *see* Saukkonen, K., 325
Portetelle, D. *see* Merza, M.S., 22
Prakongsri, S. *see* Wilde, H., 10
Prince, G.A. *see* Murphy, B.R., 533
Pryde, A. *see* Barret, A.D.T., 333
Puyaratabandhu, P. *see* Wilde, H., 10
Pyle, S.W., Morein, B., Bess Jr, J.W., Akerblom, L., Nara, P.L., Nigida Jr, S.M., Lerche, N.W., Robey, W.G., Fischinger, P.J. and Arthur, L.O. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120), 465

Quinnan Jr, G.V. *see* Gross, P.A., 303

Raghupathy, R. *see* Talwar, G.P., 97
Rahman, R. *see* Clemens, J.C., 117
Reid-Sanden, F.L. *see* Fishbein, D.B., 437
Reijnders, P.J.H. *see* Visser, I.K.G., 521
Richards, R.L., Swartz Jr, G.M., Shultz, C., Hayre, M.D., Ward, G.S., Ripley Ballou, W., Chulay, J.D., Hockmeyer, W.T., Berman, S.L. and Alving, C.R. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A, 506
Ridgeway, P. *see* McBride, B.W., 409
Ripley Ballou, W. *see* Richards, R.L., 506
Rivosecchi, P. *see* Iorio, A.M., 341
Robey, W.G. *see* Pyle, S.W., 465
Robinson, A., Ashworth, L.A.E. and Irons, L.I. Serotyping *Bordetella pertussis* strains, 491
Robinson, A., Gorringe, A.R., Funnell, S.G.P. and Fernandez, M. Serospecific protection of mice against intranasal infection with *Bordetella pertussis*, 321
Roehm Jr, R.R. *see* Shaw Jr, F.E., 425
Roets, J.M. *see* Shaw Jr, F.E., 425
Rollins, P. *see* Harry, T.O., 329
Roome, A.P.C.H. *see* Herbert, M., 395
Ross, E.M. *see* Miller, D.L. 487
Rossolini, G.M. *see* Cellesi, C., 417
Roumiantzeff, M. *see* Phanuphak, P., 249

Sack, D.A. *see* see Holmgren, J., 94
Sack, D.A. *see* Ciznar, I., 111
Sack, D.A. *see* Clemens, J.C. 117
Sack, D.A. *see* Svennerholm, A.-M., 196
Saeki, S. *see* Watanabe, K., 53
Saha, S.N. and Sen, A.K. Studies on the development of a medium with peptone and casein hydroysate for the production of foot-and-mouth disease vaccine in BHK-21 cells, 357
Saiki, I. *see* Iida, J., 225, 229
Saiki, I. *see* Sakurai, T., 269
Saiki, I. *see* Maeda, H., 275
Saito, H. *see* Watanabe, K., 53
Sakurai, T., Saiki, I., Ishida, H., Takeda, K. and Azuma, I. Lethal toxicity and adjuvant activities of synthetic TDM and its related compounds in mice, 269
Salmi, A.A. *see* Makela, M.J., 541
Samanta, H. *see* Youn, B.W., 60
Samanta, H. and Youn, B.W. Expression of hepatitis B virus surface antigen containing the pre-S region in mammalian cell culture system, 69
Samegai, Y. *see* Tamura, S., 257
Sampietro, C. *see* Torre, D., 102
Sanderlin, D.W. *see* Fishbein, D.B., 437
Sansonetti, P.J. and Arondel, J. Construction and evaluation of a double mutant of *Shigella flexneri* as a candidate for oral vaccination against Shigellosis, 443
Sansoni, A. *see* Cellesi, C., 417
Sascrina, I.N. *see* Sidorenko, E.S., 554
Saukkonen, K., Leinonen, M., Abdillahi, H. and Poolman, J.T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bacterial assay, 325
Saxena, S.N. *see* Bhandari, S.K., 478
Schlumbom, V. *see* Sturchler, D., 457
Scodeller, E.A. *see* Bellinzoni, R.C., 263
Seguin, C. *see* Trudel, M., 12
Sen, A.K. *see* Saha, S.N., 357
Setia, U. *see* Gross, P.A., 303
Seto, B. *see* Neurath, A.R., 234
Sharma, S.B. *see* Bhandari, S.K., 478
Sharma, D.P., Thomas, C., Hall, R.H., Levine, M.M. and Attridge, S.R. Significance of toxin-coregulated pili as protective antigens of *Vibrio cholerae* in the infant mouse model, 451
Shaw Jr, F.E., Guess, H.A., Roets, J.M., Mohr, F.E., Coleman, P.J., Mandel, E.J., Roehm Jr, R.R., Talley, W.S. and Hadler, S.C. The effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination, 425
Sheffield, F. *see* Jones, A.E., 300
Shiba, T. *see* Tsujimoto, M., 39
Shultz, C. *see* Richards, R.L., 506
Sidey, F.M., Furman, B.L. and Wardlaw, A.C. Effect of hyperactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice, 237
Sidorenko, E.S., Dorofeeva, L.V., Kaptsova, T.I., Steinberg, L.L., Sascrina, I.N., Sinitsyna, O.A. and Boriskin, Y.S. Experimental-scale measles and mumps vaccine production on microcarrier-grown cells, 554
Simard, C. *see* Trudel, M., 12
Singh, O. *see* Alam, A., 129
Sinitsyna, O.A. *see* Sidorenko, E.S., 554
Sirivichayakul, S. *see* Phanuphak, P., 253
Sjoholm, I. *see* O'Hagan, D.T., 421
Skinner, G.R.B. Nice work for everybody except the patient, 381
Slepushkin, A.N. *see* Obrosova-Servoa, N.P., 0
Small Jr, P.A. *see* El Guink, N., 147
Snyder, M.H. *see* Murphy, B.R., 557
Sotnikov, A. *see* Murphy, B.R., 533
Speijers, G.J.A., Danse, L.H.J.C., Krajnc-Franken, M.A.M., van Leeuwen, F.X.R., Helleman, J.G. and v.d. Heijden, C. Subacute toxicity of Zwittergent administered intramuscularly, 364
Spier, R.E. Ethical problems? Get a technical fix, 381
Sriwanthana, B. *see* Phanuphak, P., 249, 253
Stanislavsky, E.S., Edvabnaya, L.S., Bandman, O.A., Boolk, V.F., Zhvanetskaya, M.I. and Vargina, A.K. Experimental studies on the protective efficacy of a *Pseudomonas aeruginosa* vaccine, 562
Steinberg, L.L. *see* Sidorenko, E.S., 554
Strick, N. *see* Neurath, A.R., 234
Stroffolini, T., Pasquini, P., Mele, A. and Collaborating Group for Vaccination against Hepatitis B in Italy. A nationwide vaccination programme in Italy against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers, 152
Stromstedt, K. *see* Akerblom, L., 142
Strugnell, R.A. *see* Chatfield, S.N., 495
Sturchler, D., Berger, R., Etlinger, H., Fernex, M., Matile, H., Pink, R., Schlumbom, V. and Just, M. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults, 457
Sugimoto, M. *see* Watanabe, K., 53
Sumner, J.E. *see* Fishbein, D.B., 437
Supich, C. *see* Wilde, H., 49
Sureau, P. *see* Harry, T.O., 329
Svennerholm, A.-M. *see* Holmgren, J., 94
Svennerholm, A.-M. *see* Clemens, J.C., 117
Svennerholm, A.-M., Holmgren, J. and Sack, D.A. Development of oral vaccines against enterotoxinogenic *Escherichia coli* diarrhoea, 196
Svitkin, Y.V. *see* Elbert, L.B., 477
Swartz Jr, G.M. *see* Richards, R.L., 506
Szoka Jr, F.C. *see* Dal Monte, P.R., 401

Takada, H. *see* Tsujimoto, M., 39
Takahashi, K. *see* Onuma, M., 121
Takahashi, T. *see* Tsujimoto, M., 39
Takaoki, M. *see* Hazama, M., 567
Takeda, K. *see* Sakurai, T., 269
Takenaka, H. *see* Kusumi, T., 351
Talley, W.S. *see* Shaw Jr, F.E., 425
Talwar, G.P. *see* Alam, A., 129
Talwar, G.P. and Raghupathy, R. Anti-fertility vaccines, 97
Tamura, S., Samegai, Y., Kurata, H., Kikuta, K., Nagamine, T., Aizawa, C. and Kurata, T. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine, 257

Tamura, S., Kurata, K., Funato, H., Nagamine, T., Aizawa, C. and Kurata, T. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccine combined with cholera toxin B subunit, 314
Tamura, S.I., Funato, H., Nagamine, T., Aizawa, C. and Kurata, T. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB, 503
Tanaka, A. *see* Kusumi, T., 351
Terletskaya, E.N. *see* Elbert, L.B., 477
Thomas, C. *see* Sharma, D.P., 451
Timofeev, A.V. *see* Elbert, L.B., 477
Tong, T.C. *see* Fishbein, D.B., 437
Torre, D., Broggini, M., Botta, V. and Sampietro, C. Duration of immunity to hepatitis B vaccination in institutionalized mentally retarded patients, 102
Tripathi, K.K. *see* Madhusudana, S.N., 478
Tripathi, K.K. and Madhusudana, S.N. Safety of equine rabies immune globulin, 372
Trudel, M., Nadon, F., Seguin, C., Simard, C. and Lussier, G. Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus, 12
Tsujimoto, M., Kotani, S., Okunaga, T., Kubo, T., Takada, H., Kubo, T., Shiba, T., Kusumoto, S., Takahashi, T. and Goto, Y. Enhancement of humoral immune responses against viral vaccines by a non-pyrogenic 6-*O*-acylmuramyldipeptide and synthetic low toxicity analogues of lipid A, 39
Tyrell, D.L.J. *see* Makela, M.J., 541

Utaisen, O. *see* Phanuphak, P., 253
Uytde-Haag, F. *see* Osterhaus, A., 137
UytdeHaag, F.G.C.M. *see* Visser, I.K.G., 521

v.d. Bildt, M.W.G. *see* Visser, I.K.G., 521
v.d. Heijden, C.A. *see* Speijers, G.J.A., 364
Van Der Maaten, M. *see* Whetstone, C., 527
van Leeuwen, F.X.R. *see* Speijers, G.J.A., 364
Vargina, A.K. *see* Stanislavsky, E.S., 562
Vedder, E.J. *see* Visser, I.K.G., 521
Visser, I.K.G., v.d. Bildt, M.W.G., Brugge, H.N., Reijnders, P.J.H., Vedder, E.J., de Vries, P., Groen, J., Walvoort, H.C., UytdeHaag, F.G.C.M. and Osterhaus, A.D.M.E. Vaccination of harbour seals (*Phoca vitulina*) against phocid disptemper with two different inactivated canine distemper virus (CDV) vaccines, 521
von Magnus, H. *see* Pedersen, I.R., 345
Vos, J.G. *see* Speijers, G.J.A., 364

Wadsworth, M.J.H. *see* Miller, D.L., 487
Walvoort, H.C. *see* Visser, I.K.G., 521
Ward, G.S. *see* Richards, R.L., 506
Wardlaw, A.C. *see* Sidey, F.M., 237
Watanabe, K., Morita, M. and Kojima, A. Stability of recombinant vaccinia virus LC16m0 or LC16m8: preserved laboratory attenuation markers and conserved expression of inserted HBsAg gene, 499
Watanabe, K., Kobayashi, H., Kajiyama, K., Morita, M., Yasuda, A., Gotoh, H., Saeki, S., Sugimoto, M., Saito, H. and Kojima, A. Improving recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surface antigen, 53
Weijer, K. *see* Osterhaus, A., 137
Weksler, M.E. *see* Gross, P.A., 303
Welch, M.J. *see* Erturk, M., 431
Whetstone, C., Miller, J., Bortner, D. and Van Der Maaten, M. Changes in the restriction endonuclease patterns of four modified-live infectious bovine rhinotracheitis virus (IBRV) vaccines after one passage in host animal, 527
Whitby, J.E. *see* Barret, A.D.T., 333
Wiesmuller, K.-H., Jung, G. and Hess, G. Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator, 29
Wilde, H. *see* Chutivongse, S., 546
Wilde, H., Chomchey, P., Prakongsri, S., Puyaratabandhu, P. and Chutivongse, S. Adverse effects of equine rabies immune globulin, 10
Wilde, H., Choomkasien, P., Hemachudha, T., Supich, C. and Chutivongse, S. Failure of rabies postexposure treatment in Thailand, 49
Wong, D.T. *see* Piedra, P.A., 34
Wongurai, S. *see* Phanuphak, P., 249, 253

Yager, P.A. *see* Fishbein, D.B., 437
Yamada, A. *see* Kusumi, T., 351
Yamamoto, K. *see* Ishihara, C., 309
Yamamoto, M. *see* Onuma, M., 121
Yamamoto, N. *see* Ishihara, C., 309
Yasuda, A. *see* Watanabe, K., 53
Yasutomi, Y. *see* Onuma, M., 121
Yilma, T.D. Prospects for the total eradication of rinderpest, 484
Youn, B.W. *see* Samanta, H., 69
Youn, B.W. and Samanta, H. Purification and characterization of pre-S-containing hepatitis B surface antigens produced in recombinant mammalian cell culture, 60

Zajac, B.A. *see* Lydick, E., 549
Zanchi, A. *see* Cellesi, C., 417
Zei, T. *see* Iorio, A.M., 341
Zhvanetskaya, M.I. *see* Stanislavsky, E.S., 562
Zubak, J.J. *see* Murphy, B.R., 533

Subject Index

Adjuvant: Enhancement of humoral immune responses against viral vaccines by a non-pyrogenic 6-*O*-acylmuramyldipeptide and synthetic low toxicity analogues of lipid A, 39
Adjuvant: Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120), 465
Adjuvant: Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization, 213
Adjuvant: *see* Cholera toxin B subunit, 503
Adjuvant: *see* Malaria, 506
Adjuvant: *see* Sendai virus, 225
Adjuvant: *see* Trehalose dimycolate, 269
Adjuvant: *see* Lipid A analogue, 275
Adjuvant: *see* Zwittergent, 364
Adjuvant: *see* Microparticles, 421
Adjuvants: Enhancing effects of immunoactive peptide FR48217 on immunological responses to vaccination by inactivated influenza virus, 351
Adult: *see* Pertussis, 349
Agglutinogen: *see Bordetella pertussis*, 321
Anti-fertility: Anti-fertility vaccines, 97
Anti-fertility: Stability of an anti-fertility vaccine consisting of gonadotropin subunits linked to tetanus toxoid, 129
Anti-GnRH: *see* Anti-fertility, 97
Anti-hCG: *see* Anti-fertility, 97
Anti-tumour effect: *see Nocardia rubra* cell-wall skeleton, 121
Antigen presentation: *see* Cytochrome *c*, 401
Attenuation marker: *see* Vaccinia, 499
Attenuation: *see* Influenza, 557

B subunit vaccine: *see* Cholera, 257
B subunit vaccine: *see* Influenza, 314
B-cell activator: *see* Foot-and-mouth disease, 29

BHK-21 cells: *see* Foot-and-mouth disease, 357
Booster: *see* Measles, 541
Book Reviews: 81, 165, 373
Bordetella pertussis: Serospecific protection of mice against intransal infection with *Bordetella pertussis*, 321
Bordetella pertussis: Serotyping *Bordetella pertussis* strains, 491
Bovine leukaemia virus: Bovine leukaemia virus ISCOMs: biochemical characterization, 22
Bovine lymphosarcoma: see *Nocardia rubra* cell-wall skeleton, 121
Brain damage: *see* Pertussis, 199

Canine distemper virus vaccine: *see* Seal, 521
Cholera toxin B subunit: Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB, 503
Cholera: Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine, 257
Cholera: New cholera vaccines, 94
Cholera: Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. I. Cross-reacting antigens of members of family Vibrionaceae and the vaccines, 111
Cholera: Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. II. Field evaluation of cross-protection against other members of the Vibrioaceae family, 117
Cholera: *see* Influenza, 314
Cholera: *see Vibrio cholerae*, 451
Chronic disease: *see* Influenza, 303
Colloidal carrier: *see* Adjuvant, 213
Combined vaccine, *see* Rabies, 249
Conference Reports: 84, 85, 166, 285
Cotton rat: *see* Respiratory syncytial virus, 34, 533
Cross protection: *see* Cholera, 117
Cross-reactivity: *see* Cholera, 111
Cross-reactivity: *see* Streptococcus, 217
Cytochrome *c*: Antigen presentation by B cells and macrophages of cytochrome *c* and its antigenic fragment when conjugated to the surface of liposomes, 401
Cytokines: *see* Sendai virus, 229

Delayed hypersensitivity: *see* Hepatitis B, 77
Detergent-extracted: *see* Herpes simplex virus, 431
Diarrhoea, cattle: *see* Rotavirus, 263
Diphtheria toxin: *see* Poliovirus, 132
Diphtheria: Durability of immunity to diphtheria, tetanus and poliomyelitis after a three dose immunization schedule completed in the first eight months of life, 300
Diphtheria: Immunity to diphtheria in a sample of adult population from central Italy, 417
Dose schedule: *see* Hepatitis B, 106

Elderly: *see* Influenza, 303, 341, 385, 462
Endotoxin: *see* Pertussis, 237
Equine immunoglobulin: *see* Rabies, 372
Escherichia coli: Antibody response to a foreign epitope expressed at the surface of recombinant bacteria: importance of the route of immunization, 242
Escherichia coli: Development of oral vaccines against enterotoxinogenic *Escherichia coli* diarrhoea, 196
Escherichia coli: *see* Meningococcus, 17

FeLV: Formation and characterization of FeLV ISCOMs, 142
FeLV: Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine, 137
Field trial: *see* Leprosy, 92
Field trial: *see* Hepatitis B, 253
Fimbriae: *see Bordetella pertussis*, 321
Flavivirus: *see* Yellow fever, 333
Fluorometry: *see* Influenza, 104
Foot-and-mouth disease: Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator, 29
Foot-and-mouth disease: Studies on the development of a medium with peptone and casein hydroysate for the production of foot-and-mouth disease vaccine in BHK-21 cells, 357
Formalin inactivation: *see* Herpesvirus, bovine, 513

Glutaraldehyde: *see* Pertussis, 486
Glycoprotein gB-1: *see* Herpes simplex, 155
Glycoprotein: *see* Herpesvirus, bovine, 513
Glycoprotein: *see* Respiratory syncytial virus, 533
Glycoprotein: *see* Adjuvant, 465
Gonadotropin subunit: *see* Anti-fertility, 129
Group B polysaccharide: *see* Meningococcus, 17
Group B polysaccharide: *see* Streptococcus, 217

HbsAG: *see* Vaccinia, 499
HDCV: *see* Rabies, 125
Hepatitis B: A nationwide vaccination programme in Italy against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers, 152
Hepatitis B: Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective, 234
Hepatitis B: Comparative immunogenicity study of four plasma-derived hepatitis B vaccines in Thai young adults, 253
Hepatitis B: Comparison of intradermal and intramuscular hepatitis B vaccination in university students, 395
Hepatitis B: Duration of immunity to hepatitis B vaccination in institutionalized mentally retarded patients, 102
Hepatitis B: Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians, 106
Hepatitis B: Expression of hepatitis B virus surface antigen containing the pre-S region in mammalian cell culture system, 69
Hepatitis B: Immunogenicity of a new type of yeast-derived hepatitis B vaccine consisting of M (pre-S2+S) protein particles, 567
Hepatitis B: Improving recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surface antigen, 53
Hepatitis B: Purification and characterization of pre-S-containing hepatitis B surface antigens produced in recombinant mammalian cell culture, 60
Hepatitis B: The effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination, 425
Hepatitis B: Vaccine hypersensitivity or coincidental virus infection, 77
Hepatitis B: Putative failures of recombinant DNA hepatitis B vaccines, 164
Hepatitis B: *see Escherichia coli*, 242
Herpes simplex virus: Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents, 431
Herpes simplex virus: Reinfections and site-specific immunity in herpes simplex virus infection, 380
Herpes simplex virus: *see* Mucosal immunity, 409
Herpes simplex: Immunogenicity of herpes simplex virus glycoprotein gB-1-related protein produced in yeast, 155
Herpes simplex: *see* Sendai virus, 229
Herpes simplex: *see* Muramyl dipeptide analogue, 309
Herpesvirus, bovine: Effects of formalin inactivation on bovine herpesvirus-1 glycoproteins and antibody response elicited by formalin-inactivated vaccines in rabbits, 513
Herpesvirus, bovine: *see* Infectious bovine rhinotracheitis, 527
HIV: *see* Adjuvant, 465
Host resistance: *see* Muramyl dipeptide analogue, 309
Human diploid cell: *see* Rabies, 437

ICRC baccilli: *see* Leprosy, 92
Immune globulin: *see* Rabies, 10

Immune response: *see* Hepatitis B, 425
Immunization rate: *see* Influenza, 462
Infantile diarrhoea: *see* Poliovirus, 211
Infants: *see* Hepatitis B, 152
Infectious bovine rhinotracheitis: Changes in the restriction endonuclease patterns of four modified-live infectious bovine rhinotracheitis virus (IBRV) vaccines after one passage in host animal, 527
Influenza: Antibody induction by influenza vaccines in the elderly: a review of the literature, 385
Influenza: Characterization of the M protein and nucleoprotein genes of an avaian influenza A virus which are involved in host range restriction on monkeys, 557
Influenza: Factors affecting immunization rate in a cohort of elderly veterans: a retrospective pilot study of influenza vaccine compliance, 462
Influenza: Fluorometric assay for the measurement of viral neuraminidase influenza vaccines, 104
Influenza: Immune response to trivalent inactivated influenza vaccine in young and elderly subjects, 341
Influenza: Intranasal immunization with proteoliposomes protects against influenza, 147
Influenza: Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccine combined with cholera toxin B subunit, 314
Influenza: Relation of chronic disease and immune response to influenza vaccine in the elderly, 303
Influenza: *see* Cholera toxin B subunit, 503
Influenza: *see* Cholera, 257
Influenza: *see* Adjuvants, 351
Interferon: *see* Malaria, 457
Intradermal route: *see* Hepatitis B, 395
Intramuscular route: *see* Hepatitis B, 395
Intranasal immunization: *see* Influenza, 147
ISCOMs: *see* Respiratory syncytial virus, 12
ISCOMs: *see* Bovine leukaemia virus, 22
ISCOMs: *see* FeLV, 137, 142
ISCOMs: *see* Seal, 521
ISCOMs: *see* Adjuvants, 465

Killed vaccine: *see* Cholera, 94
Klebsiella proteoglycan: *see* Vulvovaginal candidiasis, 337

Leprosy: ICRC 'anti-leprosy vaccine', 92
Lipid A analogue: Adjuvant activities of synthetic lipid A subunit analogue and its conjugates with muramyl dipeptide derivatives, 275
Lipid A analogue: *see* Adjuvant, 39
Liposomal: *see* Malaria, 506
Liposome: *see* Cytochrome *c*, 401
Lung injury: *see* Respiratory syncytial virus, 34
Lymphocytic leukaemia: *see Varicella*, 549

M protein particles: *see* Hepatitis B, 567
Macrophage activation: *see* Trehalose dimycolate, 269
Macrophage activator: *see* Foot-and-mouth disease, 29
Malaria: Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults, 457
Malaria: Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A, 506
Malaria: Involvement of T cells in malaria immunity: implications for vaccine development, 3
Male sterilization: *see* Anti-fertility, 97
Measles: Antibodies to measles virus surface polypeptides in an immunized student population before and after booster vaccination, 541
Measles: Experimental-scale measles and mumps vaccine production on microcarrier-grown cells, 554
Measles: Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland, 345
Membrane proteins: *see* Influenza, 557
Meningococcus, group B: Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and *in vitro* bacterial assay, 325
Meningococcus: Passive transfer of meningococcal group B polysaccharide antibodies to the offspring of pregnant rabbits and their protective role against infection with *Escherichia coli* K1, 17
Mentally retarded: *see* Hepatitis B, 102
Microcarrier-grown: *see* Measles, 554
Microparticles: Microparticles as potentially orally active immunological adjuvants, 421
Molecular vaccine: *see* Parasites, 291
Monoclonal antibodies: *see* Meningococcus, group B, 325
Monoclonal antibodies: *see* Yellow fever, 333
Morbillivirus: A morbillivirus causing mass mortality in seals, 483
Mortality: *see* Poliovirus, 211
Mucosal immunity: Systemic and mucosal cell mediated immune responses against herpes simplex virus in vaccinated guinea-pigs detected by lymphocyte proliferation and monoclonal antibodies against macrophages and T cells, 409
Multivalent vaccine: *see Salmonella* spp., 495
Mumps: *see* Measles, 554
Muramyl dipeptide analogue: Effect of N^{α}-acetylmuramyl-L-alanyl-D-isoglutaminyl-N^{ε}-stearoyl-L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide treated mice, 309
Muramyl dipeptide analogue: *see* Adjuvant, 39
Muramyl dipeptide analogue: *see* Sendai virus, 225
Muramyl dipeptide analogue: *see* Lipid A analogue, 275
Mutant: *see Shigella flexneri*, 443
Mycobacterium leprae: *see* Leprosy, 92

Nasal vaccination: *see* Cholera toxin B subunit, 503
Neisseria meningitidis: *see* Meningococcus, group B, 325
Neuraminidase: *see* Influenza, 104
Neurological damage: *see* Pertussis, 487
Nocardia rubra cell-wall skeleton: Regression of bovine lymphosarcoma by treatment with cell-wall skeleton of *Nocardia rubra*, 121

Oil-adjuvanted vaccine: *see* Rotavirus, 263
Oral immunization: *see* Microparticles, 421
Oral immunization: *see Shigella flexneri*, 443
Oral vaccine: *see* Cholera, 94
Ovine cysticercosis: Editorial: A vaccine for ovine cysticercosis, 379

Parasites: Molecular vaccines against animal parasites, 291
Patent Reports: 78, 161, 282, 369, 474
Peptide FR48217: *see* Adjuvants, 351
Peptide vaccine: *see* Foot-and-mouth disease, 29
Pertussis: Adverse reactions and antibody response to an acellular pertussis toxoid vaccine in adult volunteers, 349
Pertussis: Editorial, 195
Pertussis: Effect of hyperactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice, 237
Pertussis: Glutaraldehyde in whole-cell *Bordetella pertussis* vaccine, 486
Pertussis: Permanent brain damage and pertussis vaccination: is the end of the saga in sight?, 199
Pertussis: Pertussis vaccine and severe acute neurological illnesses, 487
Phocid distemper: *see* Seal, 521
Plasma-derived vaccine: *see* Hepatitis B, 253
Poliomyelitis: *see* Diphtheria, 300
Poliovirus: Effect of the administration of oral poliovirus vaccine on infantile diarrhoea mortality, 211
Poliovirus: Expression of a poliovirus type 1 neutralization epitope on a diphtheria toxin fusion protein, 132
Poly(butyl-2-cyanoacrylate) particles: *see* Adjuvant, 213
Postexposure treatment: *see* Rabies, 10, 49, 329
Postexposure vaccination: *see* Rabies, 546
Postexposure: *see* Rabies, 372, 478
Potency: Loss of potency of vaccines at elevated temperatures, 479
Pre-exposure treatment: *see* Rabies, 125

Pre-exposure: *see* Purified chick embryo cell, 397
Pre-exposure: *see* Rabies, 437
Pre-S antigen: *see* Hepatitis B, 60, 69, 234
Pre-S antigen: *see Escherichia coli*, 242
Proteoliposomes: *see* Influenza, 147
Protozoa: *see* Parasites, 291
Pseudomonas aeruginosa: Experimental studies on the protective efficacy of a *Pseudomonas aeruginosa* vaccine, 562
Purified chick embryo cell: Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization, 397
Purified chick embryo cell: *see* Rabies, 478
PVRV: *see* Rabies, 125

Rabies: Adverse effects of equine rabies immune globulin, 10
Rabies: Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and the new vaccine grown on Vero cells, 125
Rabies: Failure of rabies postexposure treatment with purified chick embryo cell (PCEC) vaccine, 478
Rabies: Failure of rabies postexposure treatment in Thailand, 49
Rabies: Failures of postexposure rabies and other immunotherapies in developing countries, 372
Rabies: Human diploid cell rabies vaccine purified by zonal centrifugation: A controlled study of antibody response and side effects following primary and booster pre-exposure immunizations, 437
Rabies: Immunoenhancement with combined rabies and aluminium-adjuvanted tetanus vaccines, 249
Rabies: Postexposure rabies vaccination during pregnancy: experience with 21 patients, 546
Rabies: Safety of equine rabies immune globulin, 372
Rabies: Trial of economical regimens of suckling mouse brain rabies vaccine postexposure prophylaxis in Lagos, Nigeria, 329
Rabies: see Purified chick embryo cell, 397
Recombinant vaccine: *see* Hepatitis B, 53, 60, 69, 164
Recombinant vaccine: *see* Poliovirus, 132
Recombinant: *see* Vaccinia, 499
Reinfection: *see* Herpes simplex virus, 380
Respiratory syncytial virus: Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus, 12
Respiratory syncytial virus: Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease, 533
Respiratory syncytial virus: Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus, 34
Restriction endonuclease: *see* Infectious bovine rhinotracheitis, 527
Ribosomes: *see* Vulvovaginal candidiasis, 337
Rinderpest: Prospects for the total eradication of rinderpest, 484
Rotavirus: Efficacy of an inactivated oil-adjuvanted rotavirus vaccine in the control of calf diarrhoea in beef herds in Argentina, 263

Salmonella spp.: Live *Salmonella* as vaccines and carriers of foreign antigenic determinants, 495
Seal: Vaccination of harbour seals (*Phoca vitulina*) against phocid distemper with two different inactivated canine distemper virus (CDV) vaccines, 521
Seal: *see* Morbillivirus, 483
Sendai virus: Prophylactic activity against Sendai virus infection and macrophage activation with lipophilic derivatives of *N*-acetylglucosaminylmuramyl tri- or tetrapeptides, 225
Sendai virus: Protective activity of recombinant cytokines against Sendai virus and herpes simplex virus (HSV) infections in mice, 229
Serological survey: *see* Diptheria, 417
Serotyping: *see Bordetella pertussis*, 491
Sexually transmitted disease: Editorial, 91
Sexually transmitted disease: Ethical problems? Get a technical fix, 381
Shigella flexneri: Construction and evaluation of a double mutant of *Shigella flexneri* as a candidate for oral vaccination against Shigellosis, 443
Site-specific immunity: *see* Herpes simplex virus, 380
Sporozoite antigen: *see* Malaria, 506
Sporozoite: *see* Malaria, 457
Stability: *see* Tetanus toxoid, 478
Steroid therapy: *see* Varicella, 549
Streptococcus: Structural similarity of the type-specific group B streptococcal polysaccharides and the carbohydrate units of tissue glycoproteins: evaluation of possible cross-reactivity, 217
Subunit vaccine: *see* Respiratory syncytial virus, 12
Suckling mouse brain vaccine: *see* Rabies, 329
Surface antigen: *see* Hepatitis B, 53
Synthetic peptide: *see* Malaria, 457
Synthetic peptides: *see* Hepatitis B, 234

T cell: *see* Malaria, 3
T cell: *see* Mucosal immunity, 409
Temperatures: *see* Potency, 479
Tetanus toxoid: Tetanus toxoid (adsorbed) – a stability study, 478
Tetanus toxoid: *see* Rabies, 249
Tetanus: *see* Diphtheria, 300
Tick-borne encephalitis: Inactivated vaccine against tick-borne encephalitis (TBE) derived from heterploid continuous monkey cell line, 477
Toxin-coregulated pili: *see Vibrio cholerae*, 451
Trehalose dimycolate: Lethal toxicity and adjuvant activities of synthetic TDM and its related compounds in mice, 269
Tumor metastasis: *see* Trehalose dimycolate, 269

Vaccination programme: *see* Hepatitis B, 152
Vaccine development: Nice work for everybody except the patient, 381
Vaccinia vector: *see* Hepatitis B, 53
Vaccinia: Stability of recombinant vaccinia virus LC16m0 or LC16m8: preserved laboratory attenuation markers and conserved expression of inserted HBsAg gene, 499
Varicella: Association of steroid therapy with vaccine-associated rashes in children with acute lymphocytic leukaemic who received Oka/Merck varicella vaccine, 549
Vector: *see Salmonella* spp., 495
Vero cell: *see* Rabies, 546
Vibrio cholerae: Significance of toxin-coregulated pili as protective antigens of *Vibrio cholerae* in the infant mouse model, 451
Vibrio spp.: *see* Cholera, 111
Vibrio spp.: *see* Cholera, 117
Vulvovaginal candidiasis: Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis, 337

Yellow fever: Examination of the envelope glycoprotein of yellow fever vaccine viruses with monoclonal antibodies, 333

Zwittergent: Subacute toxicity of Zwittergent administered intramuscularly, 364